Efficacy and safety of naltrexone for amfetamine and methamfetamine use disorder: a systematic review of randomized controlled trials

References

• United Nations. United Nations Office on Drugs and Crime, World Drug Report 2017. United Nations Publication; 2017 [cited 2017 Oct 3]. Available from: https://www.unodc.org/wdr2017/field/Booklet_4_ATSNPS.pdf
   Google Scholar
• Covey DP, Bunner KD, Schuweiler DR, et al. Amphetamine elevates nucleus accumbens dopamine via an action potential-dependent mechanism that is modulated by endocannabinoids. Eur J Neurosci. 2016;43:1661–1673.
   PubMed Web of Science ®Google Scholar
• Berman SM, Kuczenski R, McCracken JT, et al. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry. 2009;14:123–142.
   PubMed Web of Science ®Google Scholar
• Barateau L, Lopez R, Dauvilliers Y. Treatment options for narcolepsy. CNS Drugs. 2016;30:369–379.
   PubMed Web of Science ®Google Scholar
• Black SW, Yamanaka A, Kilduff TS. Challenges in the development of therapeutics for narcolepsy. Prog Neurobiol. 2017;152:89–113.
   PubMed Web of Science ®Google Scholar
• Hennissen L, Bakker MJ, Banaschewski T, et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs. 2017;31:199–215.
   PubMed Web of Science ®Google Scholar
• Advokat C. What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD). Neurosci Biobehav Rev. 2010;34:1256–1266.
   PubMed Web of Science ®Google Scholar
• Adler LA, Newcorn JH. The impact, identification, and management of attention-deficit/hyperactivity disorder in adults. Introduction. CNS Spectr. 2007;12:1–2.
   PubMedGoogle Scholar
• Fleckenstein AE, Volz TJ, Riddle EL, et al. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681–698.
   PubMed Web of Science ®Google Scholar
• United Nations. United Nations Office on Drugs and Crime: amphetamines and ecstasy. Vienna (Austria): United Nations Publication; 2011 [cited 2017 Oct 3]. Available from: https://www.unodc.org/documents/ATS/ATS_Global_Assessment_2011.pdf.
   Google Scholar
• Kraemer T, Maurer HH. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther Drug Monit. 2002;24:277–289.
   PubMed Web of Science ®Google Scholar
• Sheridan J, Bennett S, Coggan C, et al. Injury associated with methamphetamine use: a review of the literature. Harm Reduct J. 2006;3:14
   PubMedGoogle Scholar
• Danks RR, Wibbenmeyer LA, Faucher LD, et al. Methamphetamine-associated burn injuries: a retrospective analysis. J Burn Care Rehabil. 2004;25:425–429.
   PubMedGoogle Scholar
• Sevak RJ, Stoops WW, Hays LR, et al. Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans. J Pharmacol Exp Ther. 2009;328:1007–1018.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012;379:55–70.
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse T. SAMHSA/CSAT treatment improvement protocols. Substance abuse treatment and family therapy. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004.
   Google Scholar
• Morley KC, Cornish JL, Faingold A, et al. Pharmacotherapeutic agents in the treatment of methamphetamine dependence. Expert Opin Investig Drugs. 2017;26:563–578.
   PubMed Web of Science ®Google Scholar
• Kampman KM. The search for medications to treat stimulant dependence. Addict Sci Clin Pract. 2008;4:28–35.
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). Arlington (VA): American Psychiatric Publishing; 2013.
   Google Scholar
• Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876–880.
   PubMed Web of Science ®Google Scholar
• O'Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49:881–887.
   PubMed Web of Science ®Google Scholar
• Helstrom AW, Blow FC, Slaymaker V, et al. Reductions in alcohol craving following naltrexone treatment for heavy drinking. Alcohol Alcohol. 2016;51:562–566.
   PubMed Web of Science ®Google Scholar
• Spanagel R, Zieglgansberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci. 1997;18:54–59.
   PubMed Web of Science ®Google Scholar
• Ray LA, Bujarski S, Courtney KE, et al. The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study. Neuropsychopharmacol. 2015;40:2347–2356.
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64:393–406.
   PubMed Web of Science ®Google Scholar
• Nestler EJ. Is there a common molecular pathway for addiction?. Nat Neurosci. 2005;8:1445
   PubMed Web of Science ®Google Scholar
• Ray LA, Chin PF, Miotto K. Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disord Drug Targets. 2010;9:13–22.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLOS Med. 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• Krupitskii EM, Blokhina EA, Verbitskaia EV, et al. Naltrexone implant treatment of polydrug dependence. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114:39–45.
   PubMedGoogle Scholar
• Mendelson J, Flower K, Coyle J, et al. A pharmacogenetic trial of naltrexone for methamphetamine dependence. Clin Pharm Ther. 2013;93:S68.
   PubMed Web of Science ®Google Scholar
• Pal R, Mendelson JE, Flower K, et al. Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study. J Addict Med. 2015;9:130–135.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Krupitsky E, Verbitskaya E, et al. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry. 2012;169:531–536.
   PubMed Web of Science ®Google Scholar
• Comer SD, Mogali S, Saccone PA, et al. Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacol. 2013;38:2427–2438.
   PubMed Web of Science ®Google Scholar
• Marks KR, Lile JA, Stoops WW, et al. Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users. Psychopharmacology 2014;231:2741–2750.
   PubMed Web of Science ®Google Scholar
• Marks KR, Lile JA, Stoops WW, et al. Separate and combined effects of naltrexone and extended-release alprazolam on the reinforcing, subject-rated, and cardiovascular effects of methamphetamine. J Clin Psychopharmacol. 2016;36:213–221.
   PubMed Web of Science ®Google Scholar
• Stoops WW, Pike E, Hays LR, et al. Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine. Pharmacol Biochem Behav. 2015;129:45–50.
   PubMed Web of Science ®Google Scholar
• Jayaram-Lindstrom N, Wennberg P, Hurd YL, et al. Effects of naltrexone on the subjective response to amphetamine in healthy volunteers. J Clin Psychopharmacol. 2004;24:665–669.
   PubMed Web of Science ®Google Scholar
• Santos GM, Coffin P, Santos D, et al. Feasibility, acceptability, and tolerability of targeted naltrexone for nondependent methamphetamine-using and binge-drinking men who have sex with men. J Acquir Immune Defic Syndr. 2016;72:21–30.
   PubMed Web of Science ®Google Scholar
• Van Kammen DP, Schulz SC. d-Amphetamine raises cortisol levels in schizophrenic patients with and without chronic naltrexone pretreatment. J Neural Transm. 1985;64:35–43.
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Kim SW. A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol. 2010;20:823–828.
   PubMed Web of Science ®Google Scholar
• Mooney LJ, Hillhouse MP, Thomas C, et al. Utilizing a two-stage design to investigate the safety and potential efficacy of monthly naltrexone plus once-daily bupropion as a treatment for methamphetamine use disorder. J Addict Med. 2016;10:236–243.
   PubMed Web of Science ®Google Scholar
• Roche DJO, Worley MJ, Courtney KE, et al. Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder. Psychopharmacology. 2017;234:1997–2007.
   PubMed Web of Science ®Google Scholar
• Kelty E, Thomson K, Carlstein S, et al. A retrospective assessment of the use of naltrexone implants for the treatment of problematic amphetamine use. Am J Addict. 2013;22:1–6.
   PubMed Web of Science ®Google Scholar
• Jayaram-Lindstrom N, Wennberg P, Beck O, et al. An open clinical trial of naltrexone for amphetamine dependence: compliance and tolerability. Nord J Psychiatry. 2005;59:167–171.
   PubMed Web of Science ®Google Scholar
• McCann DJ. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders. Clin Pharmacol Ther. 2008;83:627–630.
   PubMed Web of Science ®Google Scholar
• Jayaram-Lindstrom N, Konstenius M, Eksborg S, et al. Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacol. 2008;33:1856–1863.
   PubMed Web of Science ®Google Scholar
• Jayaram-Lindstrom N, Hammarberg A, Beck O, et al. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry. 2008;165:1442–1448.
   PubMed Web of Science ®Google Scholar
• Runarsdottir V, Hansdottir I, Tyrfingsson T, et al. Extended-release injectable naltrexone (XR-NTX) with intensive psychosocial therapy for amphetamine-dependent persons seeking treatment: a placebo-controlled trial. J Addict Med. 2017;11:197–204.
   PubMed Web of Science ®Google Scholar
• Coffin PO, Santos GM, Hern J, et al. Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial. Addiction. 2018;113:268–278.
   PubMed Web of Science ®Google Scholar
• Morean ME, de Wit H, King AC, et al. The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology. 2013;227:177–192.
   PubMed Web of Science ®Google Scholar
• MacKillop J. Factor structure of the alcohol urge questionnaire under neutral conditions and during a cue-elicited urge state. Alcohol Clin Exp Res. 2006;30:1315–1321.
   PubMed Web of Science ®Google Scholar
• Sulzer D, Sonders MS, Poulsen NW, et al. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75:406–433.
   PubMed Web of Science ®Google Scholar
• Shoblock JR, Sullivan EB, Maisonneuve IM, et al. Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. Psychopharmacology. 2003;165:359–369.
   PubMed Web of Science ®Google Scholar
• Shoblock JR, Maisonneuve IM, Glick SD. Differences between d-methamphetamine and d-amphetamine in rats: working memory, tolerance, and extinction. Psychopharmacology. 2003;170:150–156.
   PubMed Web of Science ®Google Scholar
• Calipari ES, Ferris MJ. Amphetamine mechanisms and actions at the dopamine terminal revisited. J Neurosci. 2013;33:8923–8925.
   PubMed Web of Science ®Google Scholar
• Kahlig KM, Binda F, Khoshbouei H, et al. Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A. 2005;102:3495–3500.
   PubMed Web of Science ®Google Scholar
• Keiflin R, Janak PH. Dopamine prediction errors in reward learning and addiction: from theory to neural circuitry. Neuron. 2015;88:247–263.
   PubMed Web of Science ®Google Scholar
• Ashok AH, Mizuno Y, Volkow ND, et al. Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74:511–519.
   PubMed Web of Science ®Google Scholar
• Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?. Neurosci Biobehav Rev. 2006;30:215–238.
   PubMed Web of Science ®Google Scholar
• Kuczenski R, Segal DS, Cho AK, et al. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci. 1995;15:1308–1317.
   PubMed Web of Science ®Google Scholar
• Perkins KA, Lerman C, Fonte CA, et al. Cross-validation of a new procedure for early screening of smoking cessation medications in humans. Clin Pharmacol Ther. 2010;88:109–114.
   PubMed Web of Science ®Google Scholar
• Rawson RA, Marinelli-Casey P, Anglin MD, et al. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction. 2004;99:708–717.
   PubMed Web of Science ®Google Scholar
• Schmitz JM, Stotts AL, Rhoades HM, et al. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav. 2001;26:167–180.
   PubMed Web of Science ®Google Scholar
• Lucey MR, Silverman BL, Illeperuma A, et al. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics. Alcohol Clin Exp Res. 2008;32:498–504.
   PubMed Web of Science ®Google Scholar
• Busto U, Bendayan R, Sellers EM. Clinical pharmacokinetics of non-opiate abused drugs. Clin Pharmacokinet. 1989;16:1–26.
   PubMed Web of Science ®Google Scholar
• Oliveto AH, McCance-Katz E, Singha A, et al. Effects of d-amphetamine and caffeine in humans under a cocaine discrimination procedure. Behav Pharmacol. 1998;9:207–217.
   PubMed Web of Science ®Google Scholar
• Stoops WW, Lile JA, Robbins CG, et al. The reinforcing, subject-rated, performance, and cardiovascular effects of d-amphetamine: influence of sensation-seeking status. Addict Behav. 2007;32:1177–1188.
   PubMed Web of Science ®Google Scholar
• Stoops WW, Glaser PE, Fillmore MT, et al. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. J Psychopharmacol. 2004;18:534–543.
   PubMed Web of Science ®Google Scholar
• Kish SJ. Pharmacologic mechanisms of crystal meth. CMAJ. 2008;178:1679–1682.
   PubMed Web of Science ®Google Scholar
• James D, Davies G, Willner P. The development and initial validation of a questionnaire to measure craving for amphetamine. Addiction. 2004;99:1181–1188.
   PubMed Web of Science ®Google Scholar
• Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990;13:227–236.
   PubMed Web of Science ®Google Scholar
• Carter LP, Griffiths RR. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend. 2009;105: S14–S25.
   PubMed Web of Science ®Google Scholar